Status:
NOT_YET_RECRUITING
Improving Functional Outcomes and Quality of Life in Patients With Rectal Cancer After Surgery With Intensified Follow-up & Surveillance
Lead Sponsor:
University Hospital, Basel, Switzerland
Collaborating Sponsors:
St. Claraspital AG
Clarunis - Universitäres Bauchzentrum Basel
Conditions:
LARS - Low Anterior Resection Syndrome
Rectal Cancer Surgery
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The goal of this clinical study is to gain further insights into the treatment of patients with Low Anterior Resection Syndrome (LARS) symptoms after rectal resection. The main question is: Can LARS s...
Detailed Description
Background: After surgical treatment of patients with rectal cancer, up to 65% experience a symptom complex known as LARS (Low Anterior Resection Syndrome). Those affected suffer from symptoms such as...
Eligibility Criteria
Inclusion
- patients older than 18 years
- patients with rectal cancer in the middle and lower third of the rectum in stages I to IV who underwent LAR with TME and protective ileostomy
- able to give informed consent as documented by signature
Exclusion
- dementia or other psychiatric disorder that would prevent the patients from answering the questionnaires and experiencing sustainable training effects
- impossibility of stoma reversal due to persistent anastomotic leak and/or local recurrence
Key Trial Info
Start Date :
August 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2028
Estimated Enrollment :
140 Patients enrolled
Trial Details
Trial ID
NCT06936774
Start Date
August 1 2025
End Date
July 1 2028
Last Update
July 3 2025
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Clarunis Universitäres Bauchzentrum Basel
Basel, Switzerland, 4002
2
Lindenhofspital Bern
Bern, Switzerland
3
St. Anna Spital Bern
Bern, Switzerland
4
Kantonsspital Luzern
Lucerne, Switzerland